Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:JANX NASDAQ:LEGN NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$131.60+2.9%$119.49$75.56▼$139.13$6.38B0.52439,760 shs814,360 shsJANXJanux Therapeutics$26.91+0.6%$24.24$21.73▼$71.71$1.61B2.82936,620 shs594,728 shsLEGNLegend Biotech$32.91+3.0%$34.10$27.34▼$47.79$5.90B0.231.41 million shs962,900 shsNUVLNuvalent$97.97+5.9%$80.78$55.53▼$104.44$6.67B1.3408,044 shs789,538 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+2.86%+8.63%+13.50%+28.33%+40.97%JANXJanux Therapeutics+0.56%+2.36%+14.75%+2.01%-46.21%LEGNLegend Biotech+2.97%+0.18%-3.23%-25.24%-23.23%NUVLNuvalent+5.89%+9.16%+27.78%+21.43%-5.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$131.60+2.9%$119.49$75.56▼$139.13$6.38B0.52439,760 shs814,360 shsJANXJanux Therapeutics$26.91+0.6%$24.24$21.73▼$71.71$1.61B2.82936,620 shs594,728 shsLEGNLegend Biotech$32.91+3.0%$34.10$27.34▼$47.79$5.90B0.231.41 million shs962,900 shsNUVLNuvalent$97.97+5.9%$80.78$55.53▼$104.44$6.67B1.3408,044 shs789,538 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+2.86%+8.63%+13.50%+28.33%+40.97%JANXJanux Therapeutics+0.56%+2.36%+14.75%+2.01%-46.21%LEGNLegend Biotech+2.97%+0.18%-3.23%-25.24%-23.23%NUVLNuvalent+5.89%+9.16%+27.78%+21.43%-5.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.00Buy$178.2035.41% UpsideJANXJanux Therapeutics 2.94Moderate Buy$78.31191.00% UpsideLEGNLegend Biotech 2.73Moderate Buy$66.56102.24% UpsideNUVLNuvalent 2.92Moderate Buy$120.0022.49% UpsideCurrent Analyst Ratings BreakdownLatest JANX, NUVL, AXSM, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$191.00 ➝ $194.0010/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$60.0010/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $60.0010/16/2025NUVLNuvalentStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$115.0010/15/2025NUVLNuvalentCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$135.0010/9/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$78.00 ➝ $76.0010/8/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NUVLNuvalentWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M17.03N/AN/A$1.18 per share111.53JANXJanux Therapeutics$439K3,683.67N/AN/A$19.49 per share1.38LEGNLegend Biotech$627.24M9.68N/AN/A$5.70 per share5.77NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A46.67N/A-49.88%-283.22%-33.06%11/3/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)Latest JANX, NUVL, AXSM, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LEGNLegend Biotech-$0.08N/AN/AN/A$277.91 millionN/A11/11/2025Q3 2025NUVLNuvalent-$1.38N/AN/AN/AN/AN/A11/5/2025Q3 2025JANXJanux Therapeutics-$0.60N/AN/AN/A$3.07 millionN/A11/3/2025Q3 2025AXSMAxsome Therapeutics-$0.80N/AN/AN/A$162.96 millionN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51JANXJanux TherapeuticsN/A47.0347.03LEGNLegend Biotech0.304.714.57NUVLNuvalentN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%JANXJanux Therapeutics75.39%LEGNLegend Biotech70.89%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.40%JANXJanux Therapeutics8.10%LEGNLegend Biotech0.02%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableJANX, NUVL, AXSM, and LEGN HeadlinesRecent News About These CompaniesNuvalent, Inc. $NUVL Shares Bought by TD Asset Management IncOctober 20 at 4:46 AM | marketbeat.comCantor Fitzgerald Weighs in on Nuvalent FY2025 EarningsOctober 20 at 2:18 AM | marketbeat.comNuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trialOctober 19 at 11:23 PM | msn.comNuvalent (NASDAQ:NUVL) Earns Buy Rating from Analysts at Stifel NicolausOctober 19 at 2:53 AM | americanbankingnews.comNuvalent (NASDAQ:NUVL) Insider Sells $1,134,384.16 in StockOctober 18 at 7:36 PM | marketbeat.comNuvalent (NASDAQ:NUVL) Insider Sells $1,279,018.20 in StockOctober 18 at 7:36 PM | marketbeat.comNuvalent (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 15,624 SharesOctober 18 at 7:36 PM | marketbeat.comNuvalent (NASDAQ:NUVL) CEO James Richard Porter Sells 27,000 SharesOctober 18 at 7:36 PM | marketbeat.comNuvalent (NASDAQ:NUVL) CFO Alexandra Balcom Sells 1,683 SharesOctober 18 at 4:38 PM | marketbeat.comNuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025October 18 at 6:00 AM | prnewswire.comAlexandra Balcom Sells 1,683 Shares of Nuvalent (NASDAQ:NUVL) StockOctober 18 at 5:58 AM | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 18 at 2:09 AM | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Moderate Buy" from AnalystsOctober 18 at 2:07 AM | marketbeat.comStifel Reiterates Nuvalent (NUVL) Buy RecommendationOctober 17, 2025 | msn.comNuvalent (NASDAQ:NUVL) Insider Sells $208,702.74 in StockOctober 16, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Insider Henry Pelish Sells 7,637 SharesOctober 16, 2025 | marketbeat.comAlexandra Balcom Sells 20,000 Shares of Nuvalent (NASDAQ:NUVL) StockOctober 16, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Receives Buy Rating from Stifel NicolausOctober 16, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Insider Sells $208,702.74 in StockOctober 16, 2025 | insidertrades.comCantor starts Nuvalent at Overweight, sees 60% potential upsideOctober 16, 2025 | msn.comCantor Fitzgerald Initiates Coverage of Nuvalent (NUVL) with Overweight RecommendationOctober 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJANX, NUVL, AXSM, and LEGN Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$131.60 +3.66 (+2.86%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$132.00 +0.40 (+0.30%) As of 10/20/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Janux Therapeutics NASDAQ:JANX$26.91 +0.15 (+0.56%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$27.90 +0.99 (+3.68%) As of 10/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Legend Biotech NASDAQ:LEGN$32.91 +0.95 (+2.97%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$33.22 +0.31 (+0.93%) As of 10/20/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Nuvalent NASDAQ:NUVL$97.97 +5.45 (+5.89%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$100.76 +2.79 (+2.85%) As of 10/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
